A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

Inclusion Criteria:

- Healthy male or non-pregnant female participants aged ≥ 6 calendar months to < 18
years at the time of the first study vaccination.

- For participants aged ≥ 6 months to < 9 years, born after a normal gestation period
(between 36 and 42 weeks).

- Females of childbearing potential (i.e., ovulating, pre-menopausal, not surgically
sterile) must be abstinent or be willing to use a medically accepted contraceptive
regimen for at least 2 months after vaccination. Females aged ≥ 9 years must also
return a negative urine pregnancy test at enrollment.

Exclusion Criteria:

- Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs,
chicken protein, neomycin, polymyxin, or any components of the Study Vaccine.